Related Experiment Video
Updated: Aug 18, 2025
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
Evaluation of a Novel Oncolytic Adenovirus Silencing SYVN1
Christie Vermeulen1, Tereza Brachtlova1,2,3,4, Nikki Tol1
1Amsterdam UMC location Vrije Universiteit Amsterdam, Medical Oncology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Abstract:
Oncolytic adenoviruses are promising new anticancer agents. To realize their full anticancer potential, they are being engineered to express therapeutic payloads. Tumor suppressor p53 function contributes to oncolytic adenovirus activity. Many cancer cells carry an intact TP53 gene but express p53 inhibitors that compromise p53 function. Therefore, we hypothesized that oncolytic adenoviruses could be made more effective by suppressing p53 inhibitors in selected cancer cells. To investigate this concept, we attenuated the expression of the established p53 inhibitor synoviolin (SYVN1) in A549 lung cancer cells by RNA interference. Silencing SYVN1 inhibited p53 degradation, thereby increasing p53 activity, and promoted adenovirus-induced A549 cell death. Based on these observations, we constructed a new oncolytic adenovirus that expresses a short hairpin RNA against SYVN1. This virus killed A549 cells more effectively in vitro and inhibited A549 xenograft tumor growth in vivo. Surprisingly, increased susceptibility to adenovirus-mediated cell killing by SYVN1 silencing was also observed in A549 TP53 knockout cells. Hence, while the mechanism of SYVN1-mediated inhibition of adenovirus replication is not fully understood, our results clearly show that RNA interference technology can be exploited to design more potent oncolytic adenoviruses.
Insights
Engineered oncolytic adenoviruses targeting the p53 inhibitor synoviolin (SYVN1) enhance cancer cell killing. This approach improves adenovirus efficacy, offering a new strategy for potent oncolytic virotherapy.
Area of Science:
- Oncolytic virotherapy
- Cancer biology
- Molecular oncology
Background:
- Oncolytic adenoviruses are emerging anticancer agents engineered with therapeutic payloads.
- Tumor suppressor p53 activity is crucial for oncolytic adenovirus efficacy.
- Cancer cells often inactivate p53 through inhibitors, limiting oncolytic virus effectiveness.
Purpose of the Study:
- To enhance oncolytic adenovirus potency by suppressing p53 inhibitors.
- To investigate the role of synoviolin (SYVN1) in modulating adenovirus activity.
- To develop an oncolytic adenovirus expressing short hairpin RNA against SYVN1.
Main Methods:
- RNA interference (RNAi) was used to silence SYVN1 in A549 lung cancer cells.
- A novel oncolytic adenovirus expressing shRNA against SYVN1 was constructed.
- In vitro and in vivo studies evaluated the efficacy of the engineered virus against A549 cells and xenografts.
Main Results:
- Silencing SYVN1 increased p53 activity and promoted adenovirus-induced cancer cell death.
- The engineered oncolytic adenovirus demonstrated enhanced killing of A549 cells in vitro.
- The virus significantly inhibited A549 xenograft tumor growth in vivo.
- SYVN1 silencing enhanced adenovirus-mediated cell killing even in TP53 knockout cells.
Conclusions:
- Suppression of p53 inhibitors like SYVN1 can significantly boost oncolytic adenovirus efficacy.
- RNA interference technology is a viable strategy for designing more potent oncolytic adenoviruses.
- Further research is needed to fully elucidate the mechanism of SYVN1-mediated inhibition of adenovirus replication.
